IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-30142-9.html
   My bibliography  Save this article

Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Author

Listed:
  • Patrícia M. R. Pereira

    (Memorial Sloan Kettering Cancer Center
    Mallinckrodt Institute of Radiology, Washington University School of Medicine)

  • Komal Mandleywala

    (Memorial Sloan Kettering Cancer Center)

  • Sébastien Monette

    (Weill Cornell Medicine, and The Rockefeller University)

  • Melissa Lumish

    (Memorial Sloan Kettering Cancer Center)

  • Kathryn M. Tully

    (Memorial Sloan Kettering Cancer Center
    Weill Cornell Medical College)

  • Sandeep Surendra Panikar

    (Mallinckrodt Institute of Radiology, Washington University School of Medicine)

  • Mike Cornejo

    (Memorial Sloan Kettering Cancer Center)

  • Audrey Mauguen

    (Memorial Sloan Kettering Cancer Center)

  • Ashwin Ragupathi

    (Memorial Sloan Kettering Cancer Center)

  • Nai C. Keltee

    (Mallinckrodt Institute of Radiology, Washington University School of Medicine)

  • Marissa Mattar

    (Memorial Sloan Kettering Cancer Center)

  • Yelena Y. Janjigian

    (Memorial Sloan Kettering Cancer Center)

  • Jason S. Lewis

    (Memorial Sloan Kettering Cancer Center
    Weill Cornell Medical College
    Memorial Sloan Kettering Cancer Center
    Weill Cornell Medical College)

Abstract

Resistance mechanisms and heterogeneity in HER2-positive gastric cancers (GC) limit Trastuzumab benefit in 32% of patients, and other targeted therapies have failed in clinical trials. Using patient samples, patient-derived xenografts (PDXs), partially humanized biological models, and HER2-targeted imaging technologies we demonstrate the role of caveolin-1 (CAV1) as a complementary biomarker in GC selection for Trastuzumab therapy. In retrospective analyses of samples from patients enrolled on Trastuzumab trials, the CAV1-high profile associates with low membrane HER2 density and low patient survival. We show a negative correlation between CAV1 tumoral protein levels – a major protein of cholesterol-rich membrane domains – and Trastuzumab-drug conjugate TDM1 tumor uptake. Finally, CAV1 depletion using knockdown or pharmacologic approaches (statins) increases antibody drug efficacy in tumors with incomplete HER2 membranous reactivity. In support of these findings, background statin use in patients associates with enhanced antibody efficacy. Together, this work provides preclinical justification and clinical evidence that require prospective investigation of antibody drugs combined with statins to delay drug resistance in tumors.

Suggested Citation

  • Patrícia M. R. Pereira & Komal Mandleywala & Sébastien Monette & Melissa Lumish & Kathryn M. Tully & Sandeep Surendra Panikar & Mike Cornejo & Audrey Mauguen & Ashwin Ragupathi & Nai C. Keltee & Maris, 2022. "Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30142-9
    DOI: 10.1038/s41467-022-30142-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-30142-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-30142-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. E. Bourseau-Guilmain & J. A. Menard & E. Lindqvist & V. Indira Chandran & H. C. Christianson & M. Cerezo Magaña & J. Lidfeldt & G. Marko-Varga & C. Welinder & M. Belting, 2016. "Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells," Nature Communications, Nature, vol. 7(1), pages 1-13, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Daisuke Watanabe & Michio Hiroshima & Masato Yasui & Masahiro Ueda, 2024. "Single molecule tracking based drug screening," Nature Communications, Nature, vol. 15(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30142-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.